|
|
| (5 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rivaroxaban#Adult Indications and Dosage]] |
| {{Rivaroxaban}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==1 INDICATIONS AND USAGE==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation===
| |
| XARELTO is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
| |
| | |
| There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)].
| |
| | |
| | |
| ===1.2 Treatment of Deep Vein Thrombosis===
| |
| XARELTO is indicated for the treatment of deep vein thrombosis (DVT).
| |
| | |
| | |
| ===1.3 Treatment of Pulmonary Embolism===
| |
| XARELTO is indicated for the treatment of pulmonary embolism (PE).
| |
| | |
| | |
| ===1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and of Pulmonary Embolism===
| |
| XARELTO is indicated for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.
| |
| | |
| | |
| ===1.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery===
| |
| XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XARELTO (RIVAROXABAN) TABLET, FILM COATED [JANSSEN PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]] | |